Llinks Law Offices and Freshfields Bruckhaus Deringer have represented Shanghai Henlius Biotech on its $410 million Hong Kong initial public offering, with Jian Yuan Law Offices and Sidley Austin advising the sponsors.

Backed by Chinese conglomerate Fosun International , Henlius is a biotech company which develops new drugs and biosimilars. According to its IPO prospectus, apart from one biosimilar product commercially launched in China, the company’s drug portfolio covers over 20 other products in various stages of clinical development.

Reuters added that the Henlius IPO was seen as a test for investor appetite in Hong Kong, with the IPO of Budweiser Brewing APAC, Asia’s largest listing this year,  also happening at the end of September.

The Llinks team was led by partners Chen Zhen and Zhang Zhengyi, while the Freshfields team was led by partners Grace Huang and Arun Balasubramanian.

Bank of America Merrill Lynch, CICC, Citigroup and CMB International are among the deal’s sponsors.


To contact the editorial team, please email ALBEditor@thomsonreuters.com.